ATRC

AtriCure is a high-quality, SEC-grounded growth story trading at an undemanding multiple. Revenue has compounded cleanly from $274M (FY2021) to $535M (FY2025) — five straight years of growth, +14.9% in the latest year — with a 75.0% gross margin that signals real pricing power in its atrial-fibrillation, left-atrial-appendage and pain-management franchises. The MD&A ties the growth to specific, recently-launched products (cryoSPHERE MAX, AtriClip FLEX-Mini/PRO-Mini, EnCompass clamp) rather than one-off pricing, which supports durability. Crucially, the GAAP loss is collapsing: net income improved 74.4% to -$11.4M and operating income to -$9.45M (operating margin only -1.8%), so the company sits right at the doorstep of profitability while still spending $99.2M (18.5% of revenue) on R&D.

The balance sheet and cash generation are the strongest part of the case. Operating cash flow jumped 369.8% to $57.3M against just $9.05M of capex, so the business is meaningfully free-cash-flow positive despite the accounting loss — the gap is non-cash (stock comp, amortization). Cash rose 36.4% to $167M against only $61.9M of long-term debt, and liabilities/equity is a conservative 0.33x. That self-funding profile means the narrow GAAP loss carries little solvency risk and minimal dilution (shares up just 1.9%).